Emily R Hankosky
9PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Sep 29, 2025
Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.Emily R Hankosky, Jeremie Lebrec, Clare J Lee
|Jun 24, 2025
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.Naveed Sattar, Luis-Emilio García-Pérez, Angel Rodríguez
|May 05, 2025
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.Emily R Hankosky, Xuanyao He, Raleigh Malik
|Mar 14, 2025
Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.Theresa Hunter Gibble, Chanadda Chinthammit, Jennifer M Ward
|Feb 25, 2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.Emily R Hankosky, Chanadda Chinthammit, Alexandra Meeks
|Nov 06, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.Emily R Hankosky, Hui Wang, Lisa M Neff
Pageof 2
Frequent Collaborators
2 joint publications
W Timothy Garvey
2 joint publications
Theresa Hunter Gibble
1 joint publications
Ágnes Benedict
1 joint publications
Kinga Marczell
1 joint publications
Jieling Chen
1 joint publications
J Jaime Caro
1 joint publications
Jay P Bae
1 joint publications
Brian D Benneyworth
1 joint publications
Naveed Sattar
1 joint publications
Luis-Emilio García-Pérez
